The group's principal activity is to develop therapeutic products for the treatment of severe diseases including cardiovascular and autoimmune disorders and cancer. The products include pexelizumab, eculizumab, unigraft-sci and unigraft-pd. Pexelizumab, is an antibody fragment being developed in collaboration with procter & gamble pharmaceuticals. Through its subsidiaries, the group is engaged in the discovery and development of a portfolio of additional antibody therapeutics targeting severe unmet medical needs. The columbus farming corporation was discontinued in Jan, 2004.
